Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress

뉴스 본문을 불러오고 있어요.

Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress | 웨이프 WAPE

Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress

기사 요약

관련 종목

댓글 —